IRIS Accounts Production v24.2.0.383 01509453 Board of Directors 1.7.22 31.12.23 31.12.23 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh015094532022-06-30015094532023-12-31015094532022-07-012023-12-31015094532021-06-30015094532021-07-012022-06-30015094532022-06-3001509453ns15:EnglandWales2022-07-012023-12-3101509453ns14:PoundSterling2022-07-012023-12-3101509453ns10:Director12022-07-012023-12-3101509453ns10:PrivateLimitedCompanyLtd2022-07-012023-12-3101509453ns10:SmallEntities2022-07-012023-12-3101509453ns10:AuditExempt-NoAccountantsReport2022-07-012023-12-3101509453ns10:SmallCompaniesRegimeForDirectorsReport2022-07-012023-12-3101509453ns10:SmallCompaniesRegimeForAccounts2022-07-012023-12-3101509453ns10:AbridgedAccounts2022-07-012023-12-3101509453ns10:Director22022-07-012023-12-3101509453ns10:CompanySecretary12022-07-012023-12-3101509453ns10:RegisteredOffice2022-07-012023-12-3101509453ns5:CurrentFinancialInstruments2023-12-3101509453ns5:CurrentFinancialInstruments2022-06-3001509453ns5:Non-currentFinancialInstruments2023-12-3101509453ns5:Non-currentFinancialInstruments2022-06-3001509453ns5:ShareCapital2023-12-3101509453ns5:ShareCapital2022-06-3001509453ns5:RetainedEarningsAccumulatedLosses2023-12-3101509453ns5:RetainedEarningsAccumulatedLosses2022-06-3001509453ns5:HirePurchaseContractsns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-12-3101509453ns5:HirePurchaseContractsns5:CurrentFinancialInstrumentsns5:WithinOneYear2022-06-3001509453ns5:BetweenOneFiveYearsns5:HirePurchaseContracts2023-12-3101509453ns5:BetweenOneFiveYearsns5:HirePurchaseContracts2022-06-3001509453ns5:HirePurchaseContracts2023-12-3101509453ns5:HirePurchaseContracts2022-06-30
REGISTERED NUMBER: 01509453 (England and Wales)















UNAUDITED FINANCIAL STATEMENTS

FOR THE PERIOD 1 JULY 2022 TO 31 DECEMBER 2023

FOR

PHARMEDICARE LIMITED

PHARMEDICARE LIMITED (REGISTERED NUMBER: 01509453)

CONTENTS OF THE FINANCIAL STATEMENTS
For The Period 1 July 2022 to 31 December 2023










Page

Company Information 1

Abridged Balance Sheet 2

Notes to the Financial Statements 3


PHARMEDICARE LIMITED

COMPANY INFORMATION
For The Period 1 July 2022 to 31 December 2023







DIRECTORS: S Heel
C S Shepherd





SECRETARY: S Heel





REGISTERED OFFICE: 1 Kings Mews
High Street
Godalming
Surrey
GU7 1DZ





REGISTERED NUMBER: 01509453 (England and Wales)

PHARMEDICARE LIMITED (REGISTERED NUMBER: 01509453)

ABRIDGED BALANCE SHEET
31 December 2023

2023 2022
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 15,172 63,029

CURRENT ASSETS
Debtors 43,359 78,743
Cash at bank and in hand 239 9,097
43,598 87,840
CREDITORS
Amounts falling due within one year 89,619 65,773
NET CURRENT (LIABILITIES)/ASSETS (46,021 ) 22,067
TOTAL ASSETS LESS CURRENT
LIABILITIES

(30,849

)

85,096

CREDITORS
Amounts falling due after more than one year - (51,583 )

PROVISIONS FOR LIABILITIES - (1,069 )
NET (LIABILITIES)/ASSETS (30,849 ) 32,444

CAPITAL AND RESERVES
Called up share capital 100 100
Retained earnings (30,949 ) 32,344
SHAREHOLDERS' FUNDS (30,849 ) 32,444

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the period ended 31 December 2023.

The members have not required the company to obtain an audit of its financial statements for the period ended 31 December 2023 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

All the members have consented to the preparation of an abridged Balance Sheet for the period ended 31 December 2023 in accordance with Section 444(2A) of the Companies Act 2006.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 19 August 2024 and were signed on its behalf by:



S Heel - Director


PHARMEDICARE LIMITED (REGISTERED NUMBER: 01509453)

NOTES TO THE FINANCIAL STATEMENTS
For The Period 1 July 2022 to 31 December 2023


1. STATUTORY INFORMATION

Pharmedicare Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
The financial statements have been prepared in accordance with the provisions of Section 1A ''Smaller Entities'' of Financial Reporting Standard 102 ''The Financial Reporting Standard applicable in the UK and Republic of Ireland'' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover represents sales of digital communications services in the health sector, excluding value added tax, performed during the year.

Turnover is recognised as the right to consideration arises and adjustments are made for accrued and deferred income.

Tangible fixed assets
Tangible fixed assets are stated at cost or valuation less accumulated depreciation. Cost includes costs directly attributable to making the asset capable of operating as intended by management.

Depreciation is provided at the following annual rates in order to depreciate assets over their estimated useful lives:

Plant and machinery-33.33% on cost
Fixtures and fittings-15% reducing balance
Motor Vehicles -25% on cost

Financial instruments
The company enters into basic financial instruments, which result in the recognition of financial assets and liabilities. Financial instruments are recognised at amortised cost. At the end of each reporting period financial instruments are assessed for evidence of impairment, and changes are recognised in profit or loss.

Taxation
Taxation for the year comprises current tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current tax represents the amount of tax payable or receivable in respect of the taxable profit (or loss) for the current or past reporting periods.

Deferred tax represents the future tax consequences of material transactions and events recognised in the financial statements of current and previous periods.

Current tax assets and liabilities are not discounted and are recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Hire purchase and leasing commitments
Assets acquired under finance leases or hire purchase contracts are capitalised and depreciated in the same manner as other tangible fixed assets. Payments are apportioned between the finance charge and the capital amount and the related obligations, net of future finance charges, are included in creditors.

Pension costs and other post-retirement benefits
Contributions payable to the directors pension schemes are charged to the profit and loss account in the period to which they relate. The assets of the schemes are held separately from those of the company.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the period was 2 (2022 - 2 ) .

PHARMEDICARE LIMITED (REGISTERED NUMBER: 01509453)

NOTES TO THE FINANCIAL STATEMENTS - continued
For The Period 1 July 2022 to 31 December 2023


4. TANGIBLE FIXED ASSETS
Totals
£   
COST
At 1 July 2022 152,678
Additions 3,834
Disposals (38,580 )
At 31 December 2023 117,932
DEPRECIATION
At 1 July 2022 89,649
Charge for period 33,729
Eliminated on disposal (20,618 )
At 31 December 2023 102,760
NET BOOK VALUE
At 31 December 2023 15,172
At 30 June 2022 63,029

5. LEASING AGREEMENTS

Minimum lease payments under hire purchase fall due as follows:

2023 2022
£    £   
Net obligations repayable:
Within one year 30,294 8,743
Between one and five years - 51,583
30,294 60,326

6. DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

As at 31 December 2023, the directors owed the company £28,876 (June 2022 - £35,344). This was the maximum amount owed to the company during the year, there is no interest due on the loans and they are repayable on demand.